WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”) today announced that the Compensation Committee of the Company’s Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective as of September 1, 2018. In addition to his new role as Chief Operating Officer, Mr. Pernock will continue to serve as the Company’s President.
“We are delighted to appoint David as Chief Operating Officer as we continue to build Eagle and advance to our next phase of commercialization,” said Scott Tarriff, Chief Executive Officer.
Mr. Pernock has served as President and Chief Commercial Officer of the Company since January 2017. Previously, Mr. Pernock served as a member of Eagle’s Board of Directors from April 2015 to January 2017.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s main strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the Company’s website at www.eagleus.com.
Investor Relations for Eagle Pharmaceuticals, Inc.:
In-Site Communications, Inc.
Lisa M. Wilson, 212-452-2793